SCM
IRD

Stonepine Capital Management’s Opus Genetics IRD Stock Holding History

Stonepine Capital Management’s Portfolio IRD Stock Details IRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$414K Buy
100,718
+32,030
+47% +$149K 0.23% 65
2026
Q1 		$313K Buy
+68,688
New +$238K 0.13% 64

Other funds holding IRD

CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
BCM
BIOS Capital Management Fort Worth, Texas $41.7M AUM 34.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Stonepine Capital Management's IRD Position: Q2 2026 in Review

Stonepine Capital Management increased its Opus Genetics (IRD) stake by 47% in Q2 2026, buying an estimated $149K and bringing the position to 100,718 shares worth $414K. The position accounts for 0.23% of the portfolio, ranked #65.

Stonepine Capital Management first reported a position in IRD in Q1 2026 and has held it in 2 quarters since. 103 funds tracked by Wall St. Rank hold IRD as of Q2 2026.

  • Stonepine Capital Management held 100,718 shares of Opus Genetics worth $414K as of Q2 2026.
  • Stonepine Capital Management bought 32,030 Opus Genetics shares in Q2 2026, an estimated $149K.
  • Opus Genetics made up 0.23% of Stonepine Capital Management's portfolio in Q2 2026, its #65 holding.
  • Stonepine Capital Management first reported a position in Opus Genetics in Q1 2026 and has held it in 2 quarters since.
  • 103 funds tracked by Wall St. Rank held Opus Genetics as of Q2 2026.

Based on Stonepine Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.